DRKY - ETF AI Analysis
Top Page
VistaShares Target 15 DRUKMacro Distribution ETF (DRKY)
Rating:67Neutral
Price Target:―
Positive Factors
Strong Growth Leaders in Top Holdings
Several major positions like Amazon, TSMC, Alphabet, and Woodward have shown strong recent performance, helping support the ETF’s returns.
Sector Diversification Across Growth Areas
The fund spreads its investments across health care, consumer, technology, and industrial companies, which can help reduce the impact if one sector struggles.
Recent Short-Term Performance Uptick
Despite being down so far this year, the ETF has shown a recent positive move over the last month, suggesting some improving momentum.
Negative Factors
High Concentration in a Few Stocks
A large share of the fund is tied up in a small number of holdings, so problems at those companies could significantly hurt overall performance.
Weakness in Several Key Positions
Some of the largest holdings, including Natera, Insmed, Coupang, and Mercadolibre, have had weak performance this year, which has dragged on the fund.
High Expense Ratio
The ETF charges a relatively high fee, which can eat into returns over time compared with lower-cost alternatives.
DRKY vs. SPDR S&P 500 ETF (SPY)
AUM17.35M
RegionNorth America
Expense Ratio0.95%
Beta0.94
IssuerVistaShares
Inception DateOct 08, 2025
Dividend Yield13.07%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume7,219
30 Day Avg. Volume10,291
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
DRKY Summary
DRKY is an actively managed ETF that aims to follow the overall U.S. stock market using a “total market” approach, guided by the investment ideas of Stanley Druckenmiller’s Duquesne Family Office. It holds a mix of companies across many sectors, with a big tilt toward health care, plus consumer and tech names like Amazon and Alphabet (Google). Investors might consider DRKY if they want broad stock exposure with a focus on growth and higher monthly income. However, it charges a relatively high fee and can rise or fall sharply with the stock market and its concentrated health care bets.
How much will it cost me?The expense ratio for the VistaShares Target 15 DRUKMacro Distribution ETF (Ticker: DRKY) is 0.95%, meaning you’ll pay $9.50 per year for every $1,000 invested. This is higher than average because the fund is actively managed, using sophisticated strategies and insights from the Duquesne Family Office to maximize income and returns.
What would affect this ETF?The DRKY ETF, with its strong focus on U.S. equities and significant exposure to healthcare and technology sectors, could benefit from advancements in medical innovation and tech growth, especially if economic conditions remain favorable for these industries. However, its reliance on derivative strategies and concentration in specific sectors may pose risks during periods of market volatility or regulatory changes affecting healthcare and technology. Broader economic factors, such as interest rate hikes or a slowdown in consumer spending, could also impact the ETF's performance negatively.
DRKY Top 10 Holdings
DRKY is leaning heavily into health care, with Natera as the clear star player: its rising share price and strong growth story are doing much of the heavy lifting for the fund. Insmed and NewAmsterdam, however, are more of a tug on performance, as their early-stage biotech profiles come with choppy trading and ongoing losses. On the tech side, TSMC and Roku are adding some steady-to-rising momentum, while Sea’s mixed pattern keeps it from fully pulling its weight. Despite a few foreign names, the ETF’s core exposure remains tied to the U.S. market.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Natera | 27.49% | $4.44M | $36.12B | 78.93% | 73 Outperform | |
| Insmed | 8.14% | $1.32M | $22.57B | -0.83% | 43 Neutral | |
| TSMC | 7.21% | $1.17M | $1.82T | 54.24% | 81 Outperform | |
| YPF Sociedad Anonima | 6.75% | $1.09M | $20.93B | 48.48% | 54 Neutral | |
| Sea | 5.34% | $862.47K | $65.79B | -31.95% | 69 Neutral | |
| Woodward | 5.11% | $826.09K | $24.46B | 44.84% | 79 Outperform | |
| BBB Foods, Inc. Class A | 4.67% | $754.99K | $4.81B | 54.93% | 60 Neutral | |
| Roku | 4.50% | $727.61K | $21.35B | 57.97% | 65 Neutral | |
| NewAmsterdam Pharma Company | 3.96% | $639.94K | $3.27B | 22.83% | 58 Neutral | |
| Teva Pharmaceutical | 3.61% | $582.72K | $36.27B | 106.24% | 63 Neutral |
DRKY Technical Analysis
Positive
―
Price Trends
19.91
Positive
19.46
Positive
19.38
Positive
Market Momentum
0.12
Negative
71.98
Negative
90.69
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DRKY, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 20.01, equal to the 50-day MA of 19.91, and equal to the 200-day MA of 19.38, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 71.98 is Negative, neither overbought nor oversold. The STOCH value of 90.69 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DRKY.
DRKY Peer Comparison
Comparison Results
Performance Comparison
DRKY
VistaShares Target 15 DRUKMacro Distribution ETF
21.40
3.58
20.09%
BAMD
Brookstone Dividend Stock ETF
―
―
―
STNC
Stance Equity ESG Large Cap Core ETF
―
―
―
PFOE
Pathfinder Focused Opportunities ETF
―
―
―
RFDA
RiverFront Dynamic US Dividend Advantage ETF
―
―
―
YALL
God Bless America ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents